10084816Transforming heart failure careClosedCollaborative R&DInnovate UKHeartfelt Technologies Ltd (Heartfelt) is a UK-based medical device company working to reduce heart failure (HF) hospitalisation. The catalyst for Heartfelt's inception was a statement made by a heart transplant surgeon in 2015, 'Do you know that half the people I operate on wouldn't require surgery at all if they had reported their symptoms in time?'. Heartfelt have developed a solution for "non-adherent" HF patients; mostly elderly people, often living alone, many with deteriorating mental capacity, who are unable to follow the advice given to them by their doctors. Instead of calling for help as their symptoms get worse, they end up as emergency hospital admissions. The device enables objective risk stratification of ambulatory patients in the home setting, without increasing staff load. One-fifth of the population is at risk of congestive HF, which results in direct healthcare costs of £51B/year globally. HF treatments are very effective with consistent monitoring, however, non-adherent patients, who struggle to comply with their monitoring regimes suffer repeat emergency hospitalisations contributing to \\\>60% of HF hospitalisation costs. The only automated monitoring solutions for non-adherent patients require expensive invasive surgery (£25k). Using Heartfelt's solution could reduce hospitalisations by 25%, save the NHS £217M/year and free up 165K hospital bed-days/year reducing pressure on A&E infrastructure and waiting lists. Heartfelt is developing a medical device that can autonomously track the volume of patients' feet, helping to indicate HF hospitalisation risk. The device delivers remote monitoring data to clinical teams who can optimise individual patient care and outcomes, using objective symptom data to prioritise visits for at-risk patients and reducing emergency hospitalisations. The device also helps increase equality and inclusion in healthcare, as patients from lower socioeconomic and traditionally excluded groups are more at risk of HF and non-adherence. Our project aims to further develop our device to optimise its use in a multi-patient setting as well as trialling it in 3 different NHS settings (GP, pharmacy, hospital) to gather health economics data which will be used to support the adoption of the device by the NHS and in NICE guidelines.